Generic Zyprexa Relprevv Availability
ZYPREXA RELPREVV (olanzapine pamoate - suspension, extended release;intramuscular)
Manufacturer: ELI LILLY CO
Approval date: December 11, 2009
Strength(s): EQ 210MG BASE/VIAL, EQ 300MG BASE/VIAL, EQ 405MG BASE/VIAL [RLD]
Has a generic version of Zyprexa Relprevv been approved?
No. There is currently no therapeutically equivalent version of Zyprexa Relprevv available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyprexa Relprevv. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Issued: January 2, 2001
Inventor(s): Bunnell; Charles Arthur & Ferguson; Thomas Harry & Hendriksen; Barry Arnold & Sanchez-Felix; Manuel Vicente & Tupper; David Edward
Assignee(s): Eli Lilly and Company
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.Patent expiration dates:
- September 30, 2018✓✓✓
- September 30, 2018
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- December 11, 2012 - NEW PRODUCT
- Zyprexa Relprevv Consumer Information (Drugs.com)
- Zyprexa Relprevv Consumer Information (Wolters Kluwer)
- ZyPREXA Relprevv injection Consumer Information (Cerner Multum)
- Zyprexa Relprevv Advanced Consumer Information (Micromedex)
- Olanzapine Consumer Information (Wolters Kluwer)
- Olanzapine extended-release Consumer Information (Wolters Kluwer)
- Olanzapine orally disintegrating tablets Consumer Information (Wolters Kluwer)
- Olanzapine tablets Consumer Information (Wolters Kluwer)
- Olanzapine Consumer Information (Cerner Multum)
- Olanzapine injection Consumer Information (Cerner Multum)
- Olanzapine Advanced Consumer Information (Micromedex)
- Olanzapine Intramuscular Advanced Consumer Information (Micromedex)
- Olanzapine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|